MIRA Pharmaceuticals Advances Lead Drug Ketamir-2 to Final Phase 1 Cohort, Targets Fast Track for Phase 2a
MIRA sits 63% above its 52-week low of $0.73.
Summary
MIRA Pharmaceuticals announced significant progress for its lead drug candidate, Ketamir-2, by initiating dosing in the final cohort of its Phase 1 trial and outlining plans for a Phase 2a study targeting FDA Fast Track designation.
Key Events · Product Development and Regulatory · MIRA
-
Ketamir-2 Phase 1 Progress
Initiated dosing in the final cohort of the Phase 1 multiple ascending dose (MAD) clinical trial for Ketamir-2, with 50 healthy volunteers already dosed and 6 subjects remaining. Completion is expected by the end of Q1 2026.
-
Phase 2a Study & Fast Track Designation
Finalizing plans for a Phase 2a proof-of-concept study in chemotherapy-induced peripheral neuropathy (CIPN), with anticipated initiation in Q2 2026 and intent to pursue FDA Fast Track designation due to the lack of approved therapies.
-
Upcoming Data Presentation & Partnering
Plans to present Phase 1 data for Ketamir-2 at the American Association for Cancer Research (AACR) Annual Meeting in April 2026 and engage in partnering discussions at the BIO Partnering Investment & Growth Summit in March 2026.
-
Preclinical Pipeline Update
Provided updates on preclinical programs SKNY-1 (weight loss, nicotine addiction) and MIRA-55 (inflammatory pain), aiming for IND-enabling status by year-end 2026.
Analysis · MIRA · Life Sciences
This filing provides a comprehensive positive update on MIRA Pharmaceuticals' drug development pipeline, particularly for its lead candidate, Ketamir-2. Advancing to the final cohort of a Phase 1 trial and setting a clear timeline for Phase 2a initiation demonstrates tangible progress. The intent to seek FDA Fast Track designation for chemotherapy-induced peripheral neuropathy (CIPN) is a significant positive, as it could expedite the development and regulatory review process for a condition with unmet medical needs. Upcoming presentations and partnering discussions will increase visibility and potential for future collaborations. The updates on preclinical programs also highlight a broader long-term pipeline. For a company of this size, consistent clinical progress and strategic regulatory planning are crucial for investor confidence and future value creation.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.7% of the 1739 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRA was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.7M. The 52-week trading range was $0.73 to $2.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.